09-08-2012

Celtic Pharma Holdings Advisors LLP announced that Novacta Biosystems Limited has completed a Phase I clinical trial of NVB302, the Company’s orally administered treatment for Clostridium difficile infection (“CDI”).Both single ascending dose and multiple ascending dose studies in a total of ...

more

Anglo/Russian Venture will have Important Humanitarian Objectives from Day 1

13-09-2011

Pro Bono Bio™, a new international pharmaceutical company, is the result of a three year Anglo/Russian project, developed by Celtic Pharma Holdings in London. Pro Bono Bio has ambitious growth targets that will allow it to support a unique humanitarian mission. Pro Bono Bio combines global ...

more

21-12-2010

BELLUS Health Inc. and Celtic Therapeutics announced that a global confirmatory phase III clinical study was initiated on December 14, 2010 for KIACTA™ (eprodisate). KIACTA™ is a drug candidate being developed for the treatment of AA amyloidosis, a life-threatening orphan disease that occurs ...

more

28-01-2010

Celtic Pharma Holdings Advisors LLP, the advisor to Celtic Pharma Holdings II LP (“CP2”), together with PolyTherics Limited announced an investment into a research programme to develop a novel biopharmaceutical molecule. This research programme will be undertaken jointly by PolyTherics and ...

more

Jim Mills appointed as Cantab CEO

27-01-2010

Celtic Pharma Holdings Advisors LLP announced it has made significant funding available to Cantab Biopharmaceuticals Limited for the development of improved biological medicines or ‘biosuperiors’, via the fund Celtic Pharma Holdings II LP (“CP2”). Cantab is a Cambridge, UK-based ...

more

06-10-2009

Celtic Pharma Holdings Advisors LLP, the advisor to the second Celtic Pharma fund, Celtic Pharma Holdings II LP), announced it has appointed Dr. Andy Richards to its Advisory Board. Dr. Richards is one of the UK’s biotechnology entrepreneurs with a strong track record of founding, investing ...

more